Skip to main content

LLY

Stock
Health Care
Drug Manufacturers - General

Performance overview

LLY Price
Price Chart

Forward-looking statistics

Beta
0.59
Risk
31.58%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Company info

SectorHealth Care
IndustryDrug Manufacturers - General
Employees41K
Market cap$807.8B

Fundamentals

Enterprise value$735.3B
Revenue$49.0B
Revenue per employee—
Profit margin22.67%
Debt to equity243.61

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$12.26
Dividend per share$6.00
Revenue per share$54.44
Avg trading volume (30 day)$2B
Avg trading volume (10 day)$2B
Put-call ratio—

Macro factor sensitivity

Growth+1.3
Credit+0.2
Liquidity-0.4
Inflation-1.3
Commodities+0.4
Interest Rates-0.2

Valuation

Dividend yield0.77%
PEG Ratio34.45
Price to sales14.30
P/E Ratio34.45
Enterprise Value to Revenue15.01
Price to book46.93

Upcoming events

Next earnings dayAugust 7, 2025
Next dividend day—
Ex. dividend dayAugust 15, 2025

News

Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade

Eli Lilly (LLY) closed at $762.18 in the latest trading session, marking a -1.23% move from the prior day.

Zacks Investment Research (July 21, 2025)
Ally Financial Q2 Earnings Miss on Lower Loans & Deposits

ALLY's Q2 earnings miss estimates as loan and deposit balances drop, but lower expenses and provisions offer support.

Zacks Investment Research (July 21, 2025)
Weight loss drugs could be a gamechanger for women with a common hormonal disorder

Several women who have reported improvements in symptoms of polycystic ovary syndrome, a common hormonal disorder, after using GLP-1s such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Patients and some health experts view GLP-1s as a promising potential option for a condition that lacks a standard treatment and affects millions of women in the U.S.

CNBC (July 20, 2025)
Calls of the Day: Eli Lilly and Materion

The Investment Committee debate the latest Calls of the Day.

CNBC Television (July 18, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free